Research
Hormonal
Inhibition of ceramide biosynthesis improves glucose tolerance and insulin sensitivity in obese mice by restoring insulin signaling (Akt phosphorylation) in the liver and muscle.
Blocking ceramide production improves how the body handles sugar and insulin in obese mice, primarily by fixing signaling in the liver and muscles.
GoodSupportsHIGH confidence
Inhibition of de novo ceramide synthesis improved glucose tolerance... indicative of improved insulin sensitivity... myriocin-treated obese mice showed a marked increase in Akt phosphorylation in the liver... In the muscle, inhibition of de novo ceramide enhanced both basal and insulin-mediated Akt phosphorylation.
Why this rating
Consistent findings across multiple obese mouse models.
Source
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome
Guang Yang et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009
DOI 10.1152/ajpendo.91014.2008
mechanism_onlyCited 294×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Inhibition of de novo ceramide biosynthesis using myriocin reduces body weight and fat mass in obese mice by increasing energy expenditure and metabolic rate, independent of food intake.Good
- Elevated ceramide levels contribute to the expression of inflammatory adipokines MCP-1 and PAI-1, while TNF-alpha acts upstream of ceramide biosynthesis.Good
- Inhibition of ceramide biosynthesis improves hepatic steatosis (fatty liver) in obese mice, associated with reduced hepatic SOCS-3 expression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →